drugset
drugset / Trial / NCT07401472

Study of BW-50218 in Healthy Participants

NCT07401472 ↗

Phase 1 Recruiting 60 enrolled Shanghai Argo Biopharmaceutical Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

Phase 1, Single Ascending Dose Study of Subcutaneous BW-50218 in Healthy Participants

Timeline

Start
2026-03-12
Primary completion
2027-06-30
Completion
2027-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject BW-50218 Unknown — Subcutaneous

Indications

No indication recorded.